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3-methylcrotonyl-CoA carboxylase deficiency:
Clinical, biochemical, enzymatic and molecular
studies in 88 individuals
Sarah C Grünert1,2, Martin Stucki1,3, Raphael J Morscher1, Terttu Suormala1,4, Celine Bürer1, Patricie Burda1,
Ernst Christensen5, Can Ficicioglu6, Jürgen Herwig7, Stefan Kölker8, Dorothea Möslinger9, Elisabetta Pasquini10,
René Santer11, K Otfried Schwab2, Bridget Wilcken12, Brian Fowler1,4, Wyatt W Yue13 and Matthias R Baumgartner1,3*
Abstract
Background: Isolated 3-methylcrotonyl-CoA carboxylase (MCC) deficiency is an autosomal recessive disorder of
leucine metabolism caused by mutations in MCCC1 or MCCC2 encoding the α and β subunit of MCC, respectively.
The phenotype is highly variable ranging from acute neonatal onset with fatal outcome to asymptomatic adults.
Methods: We report clinical, biochemical, enzymatic and mutation data of 88 MCC deficient individuals, 53
identified by newborn screening, 26 diagnosed due to clinical symptoms or positive family history and 9 mothers,
identified following the positive newborn screening result of their baby.
Results: Fifty-seven percent of patients were asymptomatic while 43% showed clinical symptoms, many of which
were probably not related to MCC deficiency but due to ascertainment bias. However, 12 patients (5 of 53
identified by newborn screening) presented with acute metabolic decompensations. We identified 15 novel MCCC1
and 16 novel MCCC2 mutant alleles. Additionally, we report expression studies on 3 MCCC1 and 8 MCCC2 mutations
and show an overview of all 132 MCCC1 and MCCC2 variants known to date.
Conclusions: Our data confirm that MCC deficiency, despite low penetrance, may lead to a severe clinical
phenotype resembling classical organic acidurias. However, neither the genotype nor the biochemical phenotype is
helpful in predicting the clinical course.
Keywords: 3-Methylcrotonyl-CoA carboxylase, MCCC1, MCCC2, Biotin, Inborn error, Organic aciduria, Newborn
screening
Background
Isolated 3-methylcrotonyl-CoA carboxylase (MCC) defi-
ciency (MIM#s 210200 and 210210) is an autosomal re-
cessive disorder of leucine metabolism [1]. The
mitochondrial enzyme MCC (EC 6.4.1.4) catalyzes the
fourth step in the leucine catabolic pathway and belongs
to the family of biotin-dependent carboxylases, including
acetyl-CoA carboxylase (ACC), propionyl-CoA carboxyl-
ase (PCC) and pyruvate carboxylase (PC) [1]. MCC
consists of an alpha and a beta subunit assembled into a
α6β6 dodecamer. The larger α subunit harbours the bio-
tin carboxylase (BC) domain and the biotin carboxyl car-
rier protein domain covalently bound with a biotin
prosthetic group, while the smaller β subunit contains
the carboxyltransferase (CT) domain.
Isolated MCC deficiency is caused by mutations in the
MCCC1 (formerly MCCA) or the MCCC2 (formerly
MCCB) gene coding for the α and β subunit, respectively
[2-4]. Human MCCC1 has 19 exons and maps to
chromosome region 3q25-q27, MCCC2 consists of 17
exons and has been located to chromosome region
5q12-q13 [2-4]. A total of 49 MCCC1 and 52 MCCC2
mutations have been reported so far with the majority
being missense mutations along with small insertions/
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deletions, nonsense, frameshift, and splice site mutations
[2-12].
Increased urinary levels of 3-hydroxyisovaleric acid (3-
HIVA) and 3-methylcrotonylglycine (3-MCG) are usually
found in isolated MCC deficiency. Additionally, 3-
hydroxyisovalerylcarnitine (C5OH) is characteristically
present in blood and urine. Many patients also develop a
severe secondary carnitine deficiency [1]. Surprisingly,
MCC deficiency was found to be the most frequent or-
ganic aciduria detected in tandem mass spectrometry
based newborn screening (NBS) programs in North
America [13,14], Europe [15,16] and Australia [17].
The clinical picture of MCC deficiency is heteroge-
neous and often highly variable even within the same
family [10,18]. The phenotype ranges from neonatal
onset with severe neurological involvement and even le-
thal cases [19-21] to asymptomatic adults [3,6,11,22].
Some patients develop an acute metabolic crisis usually
triggered by intercurrent infections or introduction of a
protein-rich diet in early childhood. Symptoms include
vomiting, opisthotonus, involuntary movements, sei-
zures, coma and apnoea typically associated with meta-
bolic acidosis, hypoglycemia and in some cases mild
hyperammonemia [3,7,23-27]. Others present with
neurological abnormalities such as seizures, muscular
hypotonia or developmental delay [6,18,28-31].
In contrast, the majority of children diagnosed by NBS
have been reported to have remained asymptomatic so
far [6,7,11,32]. Moreover, several asymptomatic MCC-
deficient mothers have been identified only by detection
of abnormal metabolites in the neonatal-screening sam-
ple from their healthy babies [3,6,11,22] and a number
of asymptomatic affected siblings have been identified by
family screening [33-35]. The comparative analysis of
published case reports with German NBS data indicated
that probably less than 10% of affected individuals de-
velop symptoms [6]. Therefore, MCC deficiency may be
considered to be a genetic condition with low
penetrance.
Therapeutic approaches comprise supplementation with
oral L-carnitine and a diet modestly restricted in leucine
but the efficacy of these approaches is unproven [36].
Here we summarize clinical, biochemical, enzymatic
and molecular genetic data of 88 MCC-deficient indivi-
duals, present an update of all MCCC1 and MCCC2
mutations reported to date including 15 novel MCCC1
and 16 novel MCCC2 mutations and show expression
studies of 10 missense mutations and one small deletion.
Patients and methods
Patients
Eighty-eight subjects with MCC deficiency from 78
families (10 sib-pairs) were included in this study
(Tables 1, 2, 3 and 4). Cultured fibroblasts (n = 69) or
genomic DNA (n = 16) from 85 individuals were sent to
our laboratory for confirmation of MCC deficiency. In
the remaining 3 subjects mutation analysis was per-
formed in a genetic laboratory in the USA. Forty-five
subjects were male, 40 were female; the sex of 3 indivi-
duals was not reported. Of the 88 individuals 45 (51%)
were Caucasian, 27 (31%) Turkish, 8 (9%) Arab, 6 (7%)
Asian, one (1%) African-American, and one patient (1%)
was of mixed African Caucasian ancestry.
Clinical, biochemical, enzymatic or mutation data of
32 individuals have been reported earlier [proband 20-
32a, 33-34, 36-43a, 44 and 46 [11], 30 [23], 35a and 35b
[30], 42 [37], 44 [38], 50 [28], 80 [9], 81 [39], 96a and
96c [10], and 136 [26]].
Clinical data
A questionnaire was designed and sent out to the
treating physicians. This questionnaire specifically
addressed the mode of diagnosis, clinical symptoms, the
psychomotor development, biochemical markers and
long-term treatment regimens. Additionally, in some
cases medical reports that were sent in together with the
diagnostic samples were available and used for clinical
data collection.
Cell lines and enzyme assays
Fibroblasts were cultured in a culture medium containing
10% foetal calf serum, and the activities of PCC and MCC
were assayed simultaneously in crude fibroblast homoge-
nates by measuring the incorporation of 14C-bicarbonate
into acid-non-volatile products as described earlier [40].
MCCC1 and MCCC2 mutation analysis by RT-PCR and
genomic PCR
After obtaining informed consent mutation analysis was
performed in 83 individuals. The 5 individuals in whom no
mutation analysis was performed were siblings of index
cases and presented with a metabolite profile typical for
MCC deficiency. In probands from whom RNA and DNA
were available RT-PCR amplification and sequencing of the
entire MCCC2 ORF was first performed and if no clearly
pathogenic coding alterations were detected in MCCC2,
the entire MCCC1 ORF was also analyzed. Identified muta-
tions were confirmed by PCR amplification of genomic
DNA. In individuals from whom only DNA was available
amplification of all MCCC1 and MCCC2 exons and flank-
ing intronic sequences from genomic DNA followed by
direct sequencing was performed.
RNA and genomic DNA were extracted from cultured
skin fibroblasts or peripheral blood leukocytes using the
QIAampW RNeasy or QIAampW RNA Blood Mini Kit and
the QIAampW DNA Mini Kit (Qiagen AG, Basel, Switzer-
land), respectively. The RT-PCR reaction was performed
using the One-Step RT-PCR kit (Qiagen AG, Basel,
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Table 1 Sociodemographic, biochemical, enzymatic, genetic and clinical information on 88 patients with MCC deficiency
53 Individuals identified by newborn screening without (n = 36) and with (n = 13) reported symptoms (n= 4 without clinical details)
Pt
#
Sex Ethnic
origin
Current
age (y)
Biochemical phenotype Carboxylase activities
in fibroblasts (pmol/
min/mg protein)1
Genotype Clinical phenotype§
DBS/
plasma
urine affected
gene
Nucleotide change
(at RNA level)
Amino acid change
(predicted from RNA)
C5OH 3-HIVA 3MCG MCC PCC Allele 1
Allele 2
20 f Caucasian 10 ++ ++ ++ 15.4 812 MCCC1 c.1155A>C p.R385S asymptomatic (fr)
c.559T>C p.S187P
21 f Turkish 11 ++ ++ ++ 0 530 MCCC2 c.803G>C p.R268T asymptomatic (ltf, 0.3 y)
(r.785_803del) (p.G262_R268delfs*5)
c.803G>C p.R268T
(r.785_803del) (p.G262_R268delfs*5)
22 f Turkish 12 ++ ++ ++ 5.7 587 MCCC2 c.464G>A p.R155Q asymptomatic (fr)
c.464G>A p.R155Q
23 f Arab 12 ++ ++ ++ 0 594 MCCC2 c.469C>T p.Q157* asymptomatic (ltf, 1y)
c.469C>T p.Q157*
25 m Caucasian 11 ++ ++ ++ na na MCCC1 c.872C>T◊
-
p.A291V
-
asymptomatic (ltf)
26 f Caucasian 9 ++ ++ ++ na na MCCC2 c.1690T>C◊
-
p.X564QLE
-
asymptomatic (fr)
27 f Caucasian 10 ++ ++ ++ 1.1 305 MCCC1 c.1155A>C◊
-
R385S
-
asymptomatic, but
facial dysmorphies
with hypertelorism,
mongoloid palpebral
fissures, low set ears,
mild macroglossia,
normal karyotype
46XX (ltf, 0.3 y)
29 m Turkish 10 ++ ++ ++ 1.5 723 MCCC2 c.295G>C p.E99Q asymptomatic (ltf, 6y)
c.1574+1G>A (p.F497Gfs*4)
34 m Caucasian 9 ++ ++ ++ 16.2 542 MCCC2 c.845A>G p.H282R asymptomatic (fr)
c.845A>G p.H282R
39 f Caucasian 9 ++ ++ ++ 0.7 696 MCCC2 c.517dupT p.S173Ffs*25 asymptomatic (fr)
c.1123G>T p.V375F
40 m Caucasian 9 ++ ++ ++ 5.1 620 MCCC2 c.214C>T p.R72* asymptomatic (fr)
c.416_
427del12ins16
p.T139_G143
>RWVPGEfs*35
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Table 1 Sociodemographic, biochemical, enzymatic, genetic and clinical information on 88 patients with MCC deficiency
53 Individuals identified by newborn screening without (n = 36) and with (n = 13) reported symptoms (n= 4 without clinical details) (Continued)
41 m Caucasian 8 ++ ++ ++ 0 595 MCCC1 c.694C>T◊
-
p.R232W
-
asymptomatic, mild
developmental delay
within the first years of
life, normal development
at present (fr)
43a f Caucasian 8 ++ ++ ++ 8.1 704 MCCC1 c.640_641delGG p.G214Nfs*5 asymptomatic (ltf)
c.1930G>T p.E644*
43b f Caucasian 7 ++ ++ ++ na na MCCC1 c.640_641delGG p.G214Nfs*5 asymptomatic (ltf)
c.1930G>T p.E644*
52a m Turkish 9 + + ++ 1.6 603 MCCC2 c.803G>C p.R268T asymptomatic (ltf)
(r.785_803del) (p.G262_
R268delfs*5)
c.803G>C p.R268T
(r.785_803del) (p.G262_R268delfs*5)
55 m Asian 7 ++ ++ na 18.3 634 MCCC2 c.351_353delTGG p.G118del asymptomatic (ltf, 0.6y)
c.659G>A p.G220E
56 m Turkish 7 + + ++ 9.6 359 MCCC2 c.1567A>G p.S523G asymptomatic (fr)
(exon 6 skipping) (p.V171Dfs*20)
57 m Asian 7 ++ ++ ++ 10.2 541 MCCC1 c.863A>G p.E288G asymptomatic (fr)
c.863A>G p.E288G
58 m Turkish 7 ++ ++ ++ 5.2 1046 MCCC2 c.538C>T p.R180* asymptomatic (fr)
c.538C>T p.R180*
62 m Turkish 7 ++ ++ ++ 9.5 856 MCCC1 c.873+4524_
6787del2264
p.? asymptomatic (fr)
c.873+4524_
6787del2264
p.?
64 f Turkish 8 ++ ++ ++ 9.9 762 MCCC2 c.803G>C p.R268T asymptomatic (ltf, 5y)
(r.785_803del) (p.G262_R268delfs*5)
c.803G>C p.R268T
(r.785_803del) (p.G262_R268delfs*5)
67 f Turkish 10 ++ na na 48.4 1065 MCCC2 c.464G>A p.R155Q asymptomatic (fr)
c.1015G>A p.V339M
70a f Caucasian 6 + ++ ++ 0 520 MCCC1 c.2079delA◊
-
p.V694*
-
asymptomatic (fr)
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Table 1 Sociodemographic, biochemical, enzymatic, genetic and clinical information on 88 patients with MCC deficiency
53 Individuals identified by newborn screening without (n = 36) and with (n = 13) reported symptoms (n= 4 without clinical details) (Continued)
72 m Caucasian 7 ++ ++ ++ 11.5 451 MCCC2 c.455A>C p.K152T asymptomatic (ltf)
c.903+6_
903+9delTACG
p.?
78 f Caucasian 6 ++ ++ ++ 4.8 416 MCCC2 c.671C>T p.P224L asymptomatic (fr)
c.671C>T p.P224L
82a f Caucasian 5 ++ ++ ++ 1.6 783 MCCC2 c.512-1G>A p.? asymptomatic (ltf, 1y)
c.512-1G>A p.?
82b f Caucasian 5 ++ ++ ++ na na MCCC2 c.512-1G>A p.? asymptomatic (ltf, 1y)
c.512-1G>A p.?
91 m Turkish 7 ++ + + 35.5 513 MCCC2 c.295G>C p.E99Q asymptomatic (fr)
c.295G>C p.E99Q
93b m Caucasian 8 ++ na + na na na na na asymptomatic (ltf)
107 m Caucasian 2 ++ ++ ++ 4.0 613 MCCC2 c.1073-12C>G asymptomatic (fr)
(r.1073_1216del+
r.1073insr.1073-48_
r.1073-1)
(p.G358Vfs*6+
p.G358Afs*12)
c.1073-12C>G
(r.1073_1216del+
r.1073insr.1073-48_
r.1073-1)
(p.G358Vfs*6+
p.G358Afs*12)
112 m Turkish 0.8 ++ ++ ++ 0 797 MCCC2 c.658_662delTCAGA
c.658_662delTCAGA
p.S220Tfs*15
p.S220Tfs*15
asymptomatic, however
hyperammonemia of
270 umol/l under
leucine loading test (fr)
115 f Caucasian 0.7 ++ ++ ++ 5.0 864 MCCC1 c.803C>A p.A268D asymptomatic (fr)
c.1155A>C p.R385S
125 f Arab 3 + n na 102 726 MCCC2 c.1423G>A p. G475R asymptomatic (fr)
c.1423G>A p. G475R
126 m Caucasian 3 + + na 60.6 791 MCCC2 c.1300G>C p.V434L asymptomatic (fr)
c.1300G>C p.V434L
137 m Caucasian 5 ++ ++ ++ na na MCCC2 c.518C>T p.S173L asymptomatic (fr)
c.518C>T p.S173L
138 m Caucasian 1.5 ++ ++ ++ na na MCCC1 c.1155A>C p.R385S asymptomatic (fr)
c.2009_2043del35 p.A670Dfs*34
G
rünert
et
al.O
rphanet
Journalof
Rare
D
iseases
2012,7:31
Page
5
of
24
http://w
w
w
.ojrd.com
/content/7/1/31
Table 1 Sociodemographic, biochemical, enzymatic, genetic and clinical information on 88 patients with MCC deficiency
53 Individuals identified by newborn screening without (n = 36) and with (n = 13) reported symptoms (n= 4 without clinical details) (Continued)
24 f Turkish 10 ++ ++ ++ 1.8 390 MCCC2 c.295G>C
c.295G>C
p.E99Q
p.E99Q
attention deficit
hyperactivity
disorder (fr)
28 m Caucasian 10 ++ ++ ++ 1.1 318 MCCC1 c.1155A>C
(exon 15 skipping)
p.R385S
(p.V562*)
attention deficit
hyperactivity
disorder (fr)
46 m Caucasian/
African
American
9 ++ ++ ++ 20.0 1054 MCCC1 c.2088dupA
c.1526delG
p.V697Sfs*19
p.C509Sfs*14
3 metabolic
decompensations
with vomiting,
hypoglycaemia
and ketonuria
(ltf, 7.5y)
53 f Caucasian 7 + ++ ++ 28.4 773 MCCC1 c.1155A>C
c.1315G>A
R385S
p.V439M
at the age of 6 months
minor psychomotor
delay (ltf)
59 m Faroe Islands 7 ++ ++ ++ 7.4 1051 MCCC1 c.1526delG
c.1526delG
p.C509Sfs*14
p.C509Sfs*14
muscular hypotonia,
muscle wakness,
impaired physical
performance (fr)
71 f Turkish died at
5 weeks
++ ++ ++ 1.7 597 MCCC1 c.1136G>A
c.1136G>A
p.G379D
p.G379D
metabolic crisis, floppy
infant, myoclonic jerks,
respiratory insufficiency
requiring mechanical
ventilation, deceased
at age 6 weeks
74 m African
American
6 ++ + + 23.0 749 MCCC1 c.1302T>G
c.2123dupA
p.I434M
p.H708Qfs*8
several metabolic
decompensations,
mild speech delay,
immunodeficiency due
to CD 16 deficiency (fr)
81 f Caucasian 5 + + n 21.5 233 MCCC2 c.1015G>A◊
-
p.V339M
-
Trisomy 21, psychomotor
retardation, muscular
hypotonia (fr)
90 m Turkish 7 + + + 23.8 483 MCCC2 c.295G>C
c.1015G>A
p.E99Q
p.V339M
truncal and perioral
hypotonia (fr)
105 m Caucasian 3 ++ ++ ++ 0 412 MCCC1 c.1155A>C
c.1820delG
p.R385S
p.S607Ifs*5
unpleasant odour,
failure to thrive, several
acute metabolic
decompensations with
mild hyperammonemia
during infections (fr)
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Table 1 Sociodemographic, biochemical, enzymatic, genetic and clinical information on 88 patients with MCC deficiency
53 Individuals identified by newborn screening without (n =36) and with (n = 13) reported symptoms (n =4 without clinical details) (Continued)
108 m Asian 2.5 ++ ++ ++ 0.8 456 MCCC2 c.518C>T
c.518C>T
p.S173L
p.S173L
recurrent infections,
muscular hypertonia
and hyperreflexia in
infancy (fr)
127 m Arab 2 + na na 92,9 755 MCCC2 c.1423G>C p.G475R muscle weakness (fr)
c.1423G>C p.G475R
136 f Caucasian 8 ++ ++ ++ na na MCCC2 c.1149+1G>T
c.1149+1G>T
p.?
p.?
3 metabolic
decompensations with
acidosis, hypoglycaemia,
vomiting,
encephalopathy
and coma (fr)
31 f Caucasian 10 na na na 12.4 518 MCCC1 c.1155A>C p.R385S ?
c.400G>A p.E134K
103 m Caucasian 3 ++ ++ ++ 0 545 MCCC2 (exon 7 to
14 skipping)
(p.I209Pfs*43) ?
(exon 7 to
14 skipping)
(p.I209Pfs*43)
111 ? Caucasian 1 ++ + + 34.0 1083 MCCC2 c.1015G>A p.V339M ?
c.1309A>G
(r.1309A>G+
r.1310_1373del64)
(p.I437V+
p.I437Tfs*15)
113 ? Caucasian 1 + + n 7.9 407 MCCC1 c.193A>T p.M65L ?
c.1193_1194delTG p.V398Gfs*19
1 control values measured in 53 cell lines, expressed as median value and (range): MCC activity, 305 pmol/min/mg protein (134-671); PCC activity, 583 (208-1165); ratio of PCC/MCC activity, 1.93 (1.19 – 2.58).
§information in brackets: fr followed regularly, ltf lost to follow-up, age of last follow-up, if known. + slightly elevated; ++ massively elevated; C5OH 3-hydroxyisovalerylcarnitine; DBS dried blood spots; 3-HIVA 3-
hydroxyisovaleric acid; 3-MCG 3-methylcrotonylglycine; f female; fr followed regularly; ltf lost to follow-up; m male; MCC methylcrotonyl-CoA carboxylase; n normal; na not available; NBS newborn screening; PCC
propionyl-CoA carboxylase; Pt # Patient number; RNA nd RNA not detectable; SMS selective metabolic screening; y years; ◊ mutation heterozygous on genomic PCR, homozygous in RT-PCR; # diagnosed following the
positive NBS result of their baby; ? not known.
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Table 2 Sociodemographic, biochemical, enzymatic, genetic and clinical information on 88 patients with MCC deficiency
18 individuals identified by selective metabolic screening due to clinical symptoms (n= 17, no clinical details in n=1)
Pt
#
Sex Ethnic
origin
age at
diagnosis
current
age (y)
Biochemical phenotype Carboxylase activities
in fibroblasts
(pmol/min/mg protein)1
Genotype Clinical phenotype}
DBS/
plasma
urine affected
gene
Nucleotide change
(at RNA level)
Amino acid change
(predicted from
RNA)C5OH 3-HIVA 3MCG MCC PCC Allele 1
Allele 2
30 m Turkish newborn died at 33
days
++ ++ ++ 0 637 MCCC2 c.1574+1G>A
c.1574+1G>A
(p.F497Gfs*4)
(p.F497Gfs*4)
acute decompensation on first day
of life, acidosis, hypoglycaemia,
hyperlactemia, hyperammonemia,
encephalopathy, depressed neonatal
reflexes, hypertonic episodes,
prominent hypotonia, respiratory
insufficiency requiring assisted
ventilation, cardiac arrest, patient
deceased on day 33
CT scan of the brain: multiple cysts,
ventricular dilatation, cerebral
atrophy
32a m Arab 4 years 14 ++ ++ ++ 5.0 863 MCCC2 c.127C>T
c.127C>T
p.Q43*
p.Q43*
muscular hypotonia, weakness, mild
motor delay (fr)
35a m Caucasian 9 months 16 na ++ ++ 7.3 976 MCCC2 (exon 7 to 14
skipping)
(exon 7 to 14
skipping)
(p.I209Pfs*43)
(p.I209Pfs*43)
developmental delay, familial
nystagmus, hyperopia, significant
hand tremor, mild learning disability,
failure to thrive, unpleasant odour
descibed as "smelling like cat`s
urine", hypothermia, ketonuria,
hypoglycemia and mild
hyperammonemia prior to stabilisation
on dietary therapy (ltf, 3y)
36 f Turkish 3 years 11 ++ ++ ++ 0.4 420 MCCC1 c.1527C>A
c.1527C>A
p.C509*
p.C509*
mental and speech retardation,
spasticity, impaired physical
performance (ltf)
42 f Caucasian ? 24 ++ ++ ++ 0 664 MCCC2 c.929C>G
c.929C>G
p.P310R
p.P310R
severe muscular weakness, muscle
pain (ltf, 16y)
44 m Caucasian 1.5 years 10 na ++ ++ 4.0 425 MCCC2 c.463C>T
c.463C>T
p.R155W
p.R155W
psychomotor retardation, seizures,
muscular hypotonia, metabolic
stroke, failure to thrive, clinodactyly
of the 5th fingers (fr)
50 f Arab 13 years 21 na ++ ++ 8.1 761 MCCC1 c.1882G>T
c.1114C>T
p.E628*
p.Q372*
mild Reye-like episode and
encephalitis during Influenza A
infection at age 5 years, mild
learning disability, severe attention-
deficit hyperactivity disorder,
multiple sclerosis (fr)
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Table 2 Sociodemographic, biochemical, enzymatic, genetic and clinical information on 88 patients with MCC deficiency
18 individuals identified by selective metabolic screening due to clinical symptoms (n= 17, no clinical details in n= 1) (Continued)
54 m Asian ? 13 ++ ++ ++ 1.3 1162 MCCC1 c.980C>G
c.639+2T>A
p.S327*
p.S164Rfs*3
psychomotor retardation, attention
deficit hyperactivity disorder,
frequent skin picking behaviour (ltf)
60 f Turkish ? 10 ++ ++ ++ 6.4 754 MCCC1 c.2079delA
c.2079delA
p.V694*
p.V694*
mild global psychomotor retardation,
convulsions starting at the age of 18
months during febrile episode,
continued as generalized tonic
clonic seizures after the age of 3
years, nephrolithiasis, episodes of
hematuria (ltf, 4 y)
63 m Turkish ? 8 ++ ++ na 12.0 729 MCCC2 c.464G>A
c.464G>A
p.R155Q
p.R155Q
3 metabolic decompensations with
encephalopathy, seizures, acidosis,
hypoglycemia, mild developmental
retardation
68 m Turkish 3 years 9 ++ ++ ++ 2.4 335 MCCC1 c.1155A>C
c.1155A>C
R385S
R385S
severe metabolic decompensation
with metabolic stroke, cerebral
edema and hemiparesis, mild
psychomotor retardation, seizures (fr)
77 m Arab 8 months 9 na ++ ++ 0 777 MCCC2 c.463C>T
c.463C>T
p.R155W
p.R155W
psychomotor and speech
retardation, kyphoscolisis, genu
varum, hypogammaglobulinemia,
chronic diarrhea, reversible cytopenia
under TPN (ltf, 7y)
80 m Turkish 1.5 years 9 ++ ++ n (6m)
++ (1y)
22.8 1162 MCCC2 c.116C>T
c.116C>T
p.S39F
p.S39F
speech retardation, seizures,
recurring attacks of status epilepticus
(ltf, 3y)
89 f Caucasian 7 months 10 na na na 17.0 986 MCCC2 (exon 8 to 10
skipping)
(p.K248_V334del) failure to thrive, poor feeding (ltf, 5y)
(exon 8 to 10
skipping)
(p.K248_V334del)
92 m Caucasian 1 week 5 ++ ++ ++ na na MCCC2 c.710G>A
c.1149+5G>C
p.G237D
p.?
acute metabolic crisis, mild
retardation (fr)
96a m Turkish 1 year 6 ++ ++ ++ 7.3 1212 MCCC1 c.873+
4524_6787del2264
large deletion acidosis at 1 year of age, atonic
seizures starting at 1 year of age (fr)
c.873+
4524_6787del2264
large deletion
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Table 2 Sociodemographic, biochemical, enzymatic, genetic and clinical information on 88 patients with MCC deficiency
18 individuals identified by selective metabolic screening due to clinical symptoms (n= 17, no clinical details in n= 1) (Continued)
99a f Turkish 8 years died at
8 years
++ ++ ++ na na MCCC2 c.392G>T
c.392G>T
p.C131F
p.C131F
catecholaminergic ventricular
tachycardia (mutation in RyR2 gene)
sudden cardiac death at age 8 years
69 ? Arab ? 9 na na na 18.9 1210 MCCC2 c.1567A>G p.S523G ?
c.1567A>G p.S523G
1 control values measured in 53 cell lines, expressed as median value and (range): MCC activity, 305 pmol/min/mg protein (134-671); PCC activity, 583 (208-1165); ratio of PCC/MCC activity, 1.93 (1.19 – 2.58).
§ information in brackets: fr followed regularly, ltf lost to follow-up, age of last follow-up, if known. + slightly elevated; ++ massively elevated; C5OH 3-hydroxyisovalerylcarnitine; DBS dried blood spots; 3-HIVA 3-
hydroxyisovaleric acid; 3-MCG 3-methylcrotonylglycine; f female; fr followed regularly; ltf lost to follow-up; m male; MCC methylcrotonyl-CoA carboxylase; n normal; na not available; NBS newborn screening; PCC
propionyl-CoA carboxylase; Pt # Patient number; RNA nd RNA not detectable; SMS selective metabolic screening; y years; ◊ mutation heterozygous on genomic PCR, homozygous in RT-PCR; # diagnosed following the
positive NBS result of their baby; ? not known.
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Switzerland) following the manufacturer’s instructions.
First-strand MCCC1 and MCCC2 cDNA was amplified as
described [2]. PCR products were sequenced in a thermo-
cycler and analyzed with an ABI Prism 3100 Avant using
the dye-terminator method (Applied Biosystem, Rotkreuz,
Switzerland) according to the manufacturer’s instructions.
To confirm mutations identified in RT-PCR products, a
genomic fragment containing the corresponding exon was
amplified using flanking intronic primers, and the PCR
product was sequenced directly. In cases where only
one of the two alleles could be identified in the
standard RT-PCR product all exons and flanking in-
tronic regions were sequenced. The sequences of all
primers are available upon request.
To exclude that the identified missense mutations
are common polymorphisms we amplified the rele-
vant exons from genomic DNA of 100 controls (200
alleles).
Table 3 Sociodemographic, biochemical, enzymatic, genetic and clinical information on 88 patients with MCC deficiency
8 individuals identified by family screening (asymptomatic individuals (n=3), symptomatic individuals (n=3), no clinical
data (n=2))
Pt
#
Sex Ethnic
origin
Age at
diagnosis
Current
age (y)
Biochemical
phenotype
Carboxylase
activities in
fibroblasts
(pmol/min/
mg protein)1
Genotype Clinical phenotype}
DBS/
plasma
urine affected
gene
Nucleotide
change (at
RNA level)
Amino acid
change
(predicted
from RNA)C5OH 3-HIVA 3MCG MCC PCC Allele 1
Allele 2
32b m Arab 17 years 28 ++ ++ ++ 5.3 409 na na na asymptomatic (fr)
93a m Caucasian 4 years 12 ++ + + 19.0 402 MCCC1 c.558delA p.Q186Hfs*6 asymptomatic (ltf)
c.558delA p.Q186Hfs*6
99b f Turkish 5.5 years 8 ++ ++ ++ na na na na na asymptomatic (fr)
70b m Caucasian 3.5 years 10 + + ++ na na na na na speech retardation,
muscle weakness,
hyperactivity, refusal
of meat (fr)
96c m Turkish 3 years 8 ++ ++ ++ na na MCCC1 c.873+4524_
6787del2264
large deletion mild speech retardation,
macrocephaly (ltf)
c.873+4524_
6787del2264
large deletion
35b f Caucasian 18 months 18 na ++ ++ na na na na na psychomotor retardation
(by 2 years developmental
age of 10 months), failure
to thrive, hypothermia
and ketonuria prior to
stabilisation on dietary
therapy (ltf, 1.75y)
52b m Turkish ? ? na na na na na MCCC2 c.803G>C p.R268T ?
(r.785_803del) (p.G262_
R268delfs*5)
c.803G>C p.R268T
(r.785_803del) (p.G262_
R268delfs*5)
52c m Turkish ? ? na na na na na MCCC2 c.803G>C p.R268T ?
(r.785_803del) (p.G262_
R268delfs*5)
c.803G>C p.R268T
(r.785_803del) (p.G262_
R268delfs*5)
1 control values measured in 53 cell lines, expressed as median value and (range): MCC activity, 305 pmol/min/mg protein (134-671); PCC activity, 583 (208-1165);
ratio of PCC/MCC activity, 1.93 (1.19 – 2.58).
§information in brackets: fr followed regularly, ltf lost to follow-up, age of last follow-up, if known. + slightly elevated; ++ massively elevated; C5OH 3-
hydroxyisovalerylcarnitine; DBS dried blood spots; 3-HIVA 3-hydroxyisovaleric acid; 3-MCG 3-methylcrotonylglycine; f female; fr followed regularly; ltf lost to follow-
up; m male; MCC methylcrotonyl-CoA carboxylase; n normal; na not available; NBS newborn screening; PCC propionyl-CoA carboxylase; Pt # Patient number; RNA
nd RNA not detectable; SMS selective metabolic screening; y years; ◊ mutation heterozygous on genomic PCR, homozygous in RT-PCR; # diagnosed following the
positive NBS result of their baby; ? not known.
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Table 4 Sociodemographic, biochemical, enzymatic, genetic and clinical information on 88 patients with MCC deficiency Mothers identified following the
positive newborn screening result of their offspring (n =9)
Pt
#
Sex Ethnic origin Age at
diagnosis
Current
age (y)
Biochemical phenotype Carboxylase
activities in
fibroblasts
(pmol/min/mg
protein)1
Genotype Clinical phenotype}
DBS/ plasma urine affected
gene
Nucleotide change
(at RNA level)
Amino acid
change (predicted
from RNA)
C5OH 3-HIVA 3MCG MCC PCC Allele 1
Allele 2
37 f Asian 32 years 40 ++ ++ ++ 9.6 1268 MCCC2 c.1367C>T p.A456V asymptomatic (ltf)
c.1367C>T p.A456V
51 f Asian 24 years 32 ++ na na 0 475 MCCC2 c.351_353delTGG◊
-
p.G118del
-
asymptomatic (ltf)
73c f Faroe Islands 29 years 37 ++ ++ ++ na na MCCC1 c.1526delG p.C509Sfs*14 asymptomatic (fr)
c.1526delG p.C509Sfs*14
83 f Caucasian ? 38 ++ ++ ++ na na MCCC1 c.539G>T p.G180V asymptomatic (fr)
c.558delA p.Q186Hfs*6
85 f Caucasian 38 years 49 ++ + n na na MCCC2 c.517dupT p.S173Ffs*25 asymptomatic (ltf)
c.599T>A p.I200N
100 f Caucasian 29 years 34 ++ ++ ++ na na MCCC2 c.505T>G p.Y169D asymptomatic (fr)
c.1073-12C>G
(r.1073_1216del+
r.1073insr.1073-
48_r.1073-1)
(p.G358Vfs*6+
p.G358Afs*12)
66 f Caucasian 34 years 41 + + ++ 10.0 807 MCCC2 c.436T>A
c.416_427del12ins16
p.Y146N
p.T139_G143>
RWVPGEfs*35
several metabolic crises with
hypoglycemia during febrile
illnesses, metabolic stroke,
cardiomopathy, paraesthesias (ltf)
87 f Faroe Islands 28 years 33 ++ n n 13.0 826 MCCC1 c.1526delG
c.1526delG
p.C509Sfs*14
p.C509Sfs*14
chronic tiredness (fr), otherwise
asymptomatic
33 f Turkish 36 years 45 ++ ++ ++ 4.6 520 MCCC2 c.282-1G>C p.S95_G128del ?
c.282-1G>C p.S95_G128del
1 control values measured in 53 cell lines, expressed as median value and (range): MCC activity, 305 pmol/min/mg protein (134-671); PCC activity, 583 (208-1165); ratio of PCC/MCC activity, 1.93 (1.19 – 2.58).
} information in brackets: fr followed regularly, ltf lost to follow-up, age of last follow-up, if known.
+ slightly elevated.
++ massively elevated; C5OH 3-hydroxyisovalerylcarnitine; DBS dried blood spots; 3-HIVA 3-hydroxyisovaleric acid; 3-MCG 3-methylcrotonylglycine; f female; fr followed regularly; ltf lost to follow-up; m male; MCC
methylcrotonyl-CoA carboxylase; n normal; na not available; NBS newborn screening; PCC propionyl-CoA carboxylase; Pt # Patient number; RNA nd RNA not detectable; SMS selective metabolic screening; y years;
◊ mutation heterozygous on genomic PCR, homozygous in RT-PCR; # diagnosed following the positive NBS result of their baby; ? not known.
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Construction of wild type and mutant MCCC1 and MCCC2
expression vectors and transfections
The following mutations were introduced by site-directed
mutagenesis into the existing wildtype MCCC1 and
MCCC2 pCR Blunt II TOPO vector (Invitrogen, Basel,
Switzerland): MCCC1 p.E288G, p.G379D, p.I434M and
MCCC2 p.S39F, p.G118del, p.Y146N, p.H282R, p.V434L,
p.A456V, p.G475R, p.S523G. All constructs were then
transferred into the mammalian expression vector pTra-
cer-CMV2 (Invitrogen, Basel, Switzerland) and seq-
uenced for validation. For expression studies the
constructs were transiently transfected into transformed
cultured fibroblasts deficient in either MCCC1 (homozy-
gous for c.1264_1265insG/p.Q422Rfs*10 or compound
heterozygous for c.1264_1265insG/p.Q422Rfs*10 and
c.1682-3A>G/p.N561Kfs*10) or MCCC2 (homozygous
for c.127 C>T/p.Q43*) by electroporation as described
[2]. The cells were harvested 48 hours later and assayed
for MCC and PCC activity.
Western blot analysis of expressed proteins
Western blot analysis of proteins extracted from cells har-
vested 48 h after transfection was performed as described
earlier [41]. For immunostaining of MCCC2 a commer-
cially available antibody was used (Abnova). Antiserum for
MCCC1 was produced by inoculating rabbits with peptides
corresponding to the hydrophilic strech of the last 19 C-
terminal amino acids (RHTPLVEFEEEESDKRESE) of
human MCCC1 conjugated to keyhole limpet hemocyanin
(Covance, Denver, Colorado). β-Actin was stained as
control.
The biotin-containing MCC and PCC α-subunits and PC
were also stained using streptavidin-alkaline phosphatase
followed by colorimetric detection (Transcend™ Non-
Radioactive Translation Detection Systems Kit, Promega,
Dübendorf, Switzerland).
In silico prediction of functional relevance of identified
mutations
The human MCCC1/2 enzyme has not been structurally
characterized. Missense mutations were therefore inter-
preted structurally using the homologous structure of
Pseudomonas aeruginosa MCC holoenzyme (PDB code
3U9T). Amino acid sequence alignment of MCCC1/2,
ACC1/2, PCCα/β sequences was constructed using the
ICM-Pro program (Molsoft, San Diego) with the imple-
mented alignment algorithm. The protein sequences
NG_008100.1 and NG_008882.1 [GenBank at the NCBI]
were used as reference sequences for the alpha and beta
subunit of MCC, respectively.
Results
A comprehensive summary of clinical, biochemical, en-
zymatic and molecular genetic information on each pa-
tient is given in Tables 1, 2, 3 and 4.
Diagnosis of MCC deficiency was confirmed by assaying
MCC and PCC activities in fibroblasts of 68 individuals. In
50 cell lines MCC activity was severely reduced to less
than 5% of the median control value. In 16 further cell
lines residual MCC activity varied between 5.1% and 20%
and in 2 cell lines MCC activity was 31% and 34% of the
control value. All cell lines had a highly increased PCC/
MCC activity ratio of at least 7.1. From 20 subjects fibro-
blasts were not available and the diagnosis was confirmed
by mutation analysis using genomic DNA.
Clinical data
Twenty-six individuals (30%) were diagnosed by selective
metabolic screening (SMS) due to clinical symptoms
(n = 18) or a positive family history (n = 8) while 53 indi-
viduals (60%) were identified by expanded NBS.
Additionally, 9 mothers (10%) were diagnosed following
a positive NBS result of their healthy offspring. In
patients in whom a metabolic work-up was initiated due
to clinical symptoms age at diagnosis ranged between
one week and 13 years (median 1.5 years) (Table 2).
Patients identified by family screening had a median age
at diagnosis of 3.75 years (range 1.5-17 years) (Table 3),
and mothers were diagnosed at a median age of
30.5 years (range 24-38 years) (Table 4).
Clinical information was available from 80 individuals.
Parental consanguinity was reported in 31 subjects with
most parents being second-degree relatives. Fourty-four
parents were non-consanguineous and of 13 individuals
no information on consanguinity was available. Three
children had deceased, two during an acute metabolic
decompensation at the age of 33 days and 6 weeks, and
the third, a 8-year-old girl with sudden cardiac death
due to catecholaminergic polymorphic ventricular tachy-
cardia (mutations in RyR2 gene).
In 34 (43%) of 80 subjects clinical symptoms were
reported ranging from acute metabolic decompensation
with ketoacidosis, hypoglycemia and encephalopathy to
neuromuscular symptoms, mental retardation or atten-
tion deficit hyperactivity disorders (Figure 1). Twelve
patients, 5 of which were diagnosed by newborn screen-
ing, had at least one acute metabolic decompensation.
The most common clinical symptoms of acute crises
were vomiting and encephalopathy with impaired con-
ciousness. Neurologic symptoms like seizures, metabolic
stroke, hemiparesis and cerebral edema were less fre-
quent. The most common laboratory findings were acid-
osis and hypoglycaemia. Among chronic symptoms
mental retardation including speech retardation were
the most common findings followed by seizures, muscu-
lar hypotonia, muscle weakness, muscle pain and failure
to thrive. In 5 patients an attention deficit hyperactivity
disorder was reported.
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Thirty-five out of 61 (57%) living individuals of whom
recent follow-up information was available or who had
been followed for at least until the age of three years have
remained asymptomatic. Notably, 25 (69%) of the 36 sub-
jects identified by NBS of whom either recent information
or follow-up data until the age of at least three years were
available, have remained without symptoms.
Sixty-nine out of 75 individuals of whom information on
treatment was available received dietary and/or medical
therapy. Forty individuals were given a protein-restricted or
leucine-restricted diet (which was stopped later in life in
some cases) and in 23 a leucine-free amino acid mixture
was administered at least temporarily. In 30 subjects oral
biotin was given on a trial basis. 63 patients were supple-
mented with oral carnitine, and 10 patients received oral
glycine.
Biochemical phenotype at diagnosis
Presence of C5OH in blood or dried blood spots and pres-
ence of elevated urinary excretion of 3-HIVA and 3-MCG
at the time of diagnosis are shown in Tables 1, 2, 3 and 4. A
biochemical phenotype characteristic for MCC deficiency
with elevated excretion of 3-HIVA and/or 3-MCG, defined
as more than twice the upper normal value, was found in
85% (68/80) of individuals. In 14% (11/80) only mildly ele-
vated excretion was detected. In one patient (1%) no ele-
vated excretion of 3-HIVA and 3-MCG was detected.
Notably, 5 individuals including one patient reported earlier
[39] did not excrete 3-MCG, the pathognomonic metabol-
ite of MCC deficiency. However, one of these individuals
showed massive excretion of 3-MCG when re-evaluated
6 months later.
C5OH in dried blood spots was highly elevated in 85%
(66/78) and slightly (less than twice the upper normal
value) elevated in 15% (12/78) of individuals. Low C5OH
concentrations were not always linked with low urinary
excretion of metabolites and vice versa.
In 43/68 individuals (63%) a secondary carnitine defi-
ciency was present. Remarkably, 24 (60%) of those 40
children identified through NBS of whom information
on free carnitine concentrations was available had
decreased free carnitine levels already at the time of
diagnosis or within the neonatal period. In 15 of them
free carnitine concentration was below 5 μmol/l.
Mutation analysis
Of the 83 individuals in whom mutation analysis was
performed, 31 had mutations in MCCC1 and 52 in
MCCC2 (Tables 1, 2, 3 and 4). Forty-eight probands
were found to be homozygous (12 for MCCC1 muta-
tions and 36 for MCCC2 mutations) while 28 were
compound heterozygous (15 for MCCC1 mutations
and 13 for MCCC2 mutations). In 5 of these patients
RT-PCR results showed exon skipping either for one
or both alleles, but the underlying genomic mutation
could not be identified. In the remaining 7 subjects
(4 MCCC1 and 3 MCCC2) it was not possible to de-
tect a second mutation in spite of sequencing all
exons and flanking intronic sequences. However, the
mutant allele identified appeared to be homozygous
in RT-PCR, but was clearly heterozygous in genomic
DNA. This suggests that the steady state level of
mRNA from the second allele was not detectable as
would be the case for a promoter mutation or an
intragenic deletion or insertion missed by genomic
PCR.
We identified a total of 15 novel MCCC1 and 16 novel
MCCC2 mutations (shown in bold in Tables 5 and 6). The
15 novel MCCC1 mutations comprise 7 missense, 2 non-
sense, 1 splice site and 5 frameshift mutations (5 due to
small deletions and one due to a small insertion). The 16
novel MCCC2 variants include 11 missense and 4 splice
site mutations and 1 deletion of a single amino acid.
Expression studies and Western blot analysis
The functional consequences of three MCCC1 (p.E288G,
p.G379D, p.I434M) and 8 MCCC2 (p.S39F, p.G118del,
p.Y146N, p.H282R, p.V434L, p.A456V, p.G475R and
p.S523G) mutations were investigated by expression studies
(Table 7). The MCCC1 p.E288G and p.G379D mutations
showed no residual activity while the p.I434M mutant allele
yielded on average 46% of MCC1 wildtype activity.
Only one of the MCCC2 mutations, p.A456V, showed
virtually no enzyme activity whereas seven mutations were
found to have residual activity ranging on average from 9
to 84% of MCC2 wildtype activity. Western blot analysis
of the expressed proteins revealed virtually wildtype levels
for the MCCC1 p.I434M protein while the levels of
MCCC1 p.E288G and MCCC1 p.G379D proteins were
Figure 1 Clinical manifestation of 33 symptomatic individuals
with MCC deficiency. One patient who died of sudden cardiac
arrest at the age of 8 years was excluded from this figure as
catecholaminergic ventricular tachycardia with mutations in the RyR2
gene was identified as a likely cause for the cardiac symptoms.
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Table 5 Overview on 64 MCCC1 mutant alleles and their consequences
Exon/Intron Nucleotide change
at cDNA level
Amino acid
change (at RNA level)
Consequence Patients, in whom this mutation
was found in this study/
Reference of first description
of the mutation
exon 1 c.43GC>T p.E15* nonsense Morscher et al. 2012
intron 1 c.89+2_89+34del p.? splice Morscher et al. 2012
intron 2 c.137-2A>G p.? splice Stadler et al. 2006
exon 3 c.137G>A p.G46E missense Nguyen et al. 2011
exon 3 c.168C>G p.N56K missense Morscher et al. 2012
exon 3 c.193A>T p.M65L missense #113/ This study
exon 3 c.227_228delTG p.V76Gfs*4 frameshift unpublisheda
exon 3 c.251_252delGAb p.R84Kfs*10 deletion/frameshift Stadler et al. 2006
exon 4 c.369G>C p.Q123H missense Stadler et al. 2006
exon 5 c.375C>G p.I125M missense Stadler et al. 2006
exon 5 c.400G>A p.E134K missense #32/ Dantas et al. 2005
exon 5 c.479T>G p.M160R missense Stadler et al. 2006
exon 6 c.539G>T p.G180V missense #83/ This study
exon 6 c.558delA p.Q186Hfs*6 deletion/frameshift #83, 93a/ Morscher et al. 2012
exon 6 c.559T>C p.S187P missense #20, Dantas et al. 2005
intron 6 c.639+2T>A p.S164Rfs*3 splice, exon 6 skipping #54/ This study
exon 7 c.640_641delGG p.G214Nfs*5c deletion/frameshift #43a, 43b/ Dantas et al. 2005
exon 7 c.658_662delTCAGA p.S220Tfs*15 deletion/frameshift #112/ This study
exon 7 c.694C>T p.R232W missense #41/ Dantas et al. 2005
intron 7 c.762-1G>A p. ? splice Nguyen et al. 2011
exon 8 c.803C>A p.A268D missense #115/ This study
exon 8 c.841C>T p.R281* nonsense Morscher et al. 2012
exon 8 c.842G>A p.R281Q missense Morscher et al. 2012
exon 8 c.863A>G p.E288G missense #57/ This study
exon 8 c.866C>T p.A289V missense Baumgartner et al. 2001
exon 8 c.872C>T p.A291V missense #25/ Dantas et al. 2005
intron 8 +
exon 9
c.873+4524_6787del2264 2 transkripts:
p.P292Gfs*18
p.P292_R361del
large deletion,
exon 9 and exon 9
and 10 skipping
#62, 96a, 96c/ Eminoglu et al. 2009
exon 9 c.901_902delAA p.K301Afs*10 deletion/
frameshift
Uematsu et al. 2007
exon 9 c.945T>A p.Y315* nonsense Stadler et al. 2006
exon 10 c.974T>G p.M325R missense Gallardo et al. 2001
exon 10 c.980C>G p.S327* nonsense #54/ Morscher et al. 2012
exon 10 not published p.Q372P missense Desviat et al. 2003
exon 11 c.1114C>T p.Q372* nonsense #50/ This study
exon 11 c.1135G>A p.G379S missense Stadler et al. 2006
exon 11 c.1136G>A p.G379D missense #71/ This study
exon 11 c.1139A>C p.H380P missense Morscher et al. 2012
exon 11 c.1155A>C p.R385S missense #20, 27, 28, 31, 53, 68, 105, 115, 138/
Baumgartner et al. 2001, Gallardo et al. 2001
exon 11 c.1193_1194delTG p.V398Gfs*19 deletion/frameshift #113/ This study
exon 11 c.1225C>T p.R409* nonsense Stadler et al. 2006
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severely reduced or not detectable (Figure 2). Five of the 8
expressed MCCC2 proteins (p.Y146N, p.H282R, p.A456V,
p.G475R and p.S523G) were detected at normal or only
slightly reduced levels, while the p.S39F and p.V434L pro-
tein levels were severely reduced and no protein was de-
tectable after transfection with the p.G118del construct
(Figure 3).
Discussion
This study summarizes clinical, biochemical, enzymatic and
mutation data on 88 MCC deficient individuals and sum-
marizes allMCCC1 andMCCC2mutations described so far.
Clinical phenotype
MCC deficiency has been described as a genetic condition
with low clinical penetrance [6]. Results of a comparative
analysis of case reports with NBS data reported by Stadler
and co-workers [6] suggest that less than 10% of affected
individuals ever develop minor symptoms and only less
than 1 to 2% might have a risk for severe adverse outcome.
In their study all 14 individuals diagnosed by NBS remained
asymptomatic during a follow-up period of 1.75 to 6.5 years.
In contrast, in our study only 69% of the 36 subjects identi-
fied by NBS with a follow-up of at least 3 years have stayed
completely asymptomatic while the remainder (31% =11)
developed clinical symptoms including various neurologic
symptoms as well as at least one acute metabolic decom-
pensation in 5 children. This indicates that early diagnosis
with concomitant early initiation of therapy and counselling
of parents cannot prevent a clinical manifestation in all
cases. However, our data have to be interpreted with cau-
tion, since the source of patients being those sent to a
diagnostic referral laboratory may lead to a selection bias in
favour of symptomatic individuals since it can be assumed
Table 5 Overview on 64 MCCC1 mutant alleles and their consequences (Continued)
exon 11 c.1264_1265insGd p.Q422Rfs*10d insertion/frameshift Baumgartner et al. 2001
intron 11 c.1268-2A>G p.G423Efs*15 splice, exon 12/13 skipping Stadler et al. 2006
exon 12 c.1302T>G p.I434M missense #74/ This study
exon 12 c.1310T>C p.L437P missense Baumgartner et al. 2001
exon 12 c.1315G>A p.V439M missense #53/ This study
exon 12 c.1333C>T p.Q445* nonsense Morscher et al. 2011
exon13 c.1380T>G p.I460M missense Uematsu et al. 2007
exon 13 c.1522_1544del p.L508Hfs*17 deletion Morscher et al. 2012
exon 13 c.1526delGe p.C509Sfs*14 deletion/frameshift #46, 59, 73c, 87/ Dantas et al. 2005
exon 13 c.1527C>A p.C509* nonsense #36/ Dantas et al. 2005
exon 13 c.1541dupG p.L515Sfs*18 insertion/frameshift Morscher et al. 2012
exon 13 c.1594G>C p.D532H splice Baumgartner et al. 2001
intron 13 c.1594+3A>G p.V461Nfs*13 splice, exon 13 skipping Morscher et al. 2012
exon 14 c.1604C>T p.S535F missense Holzinger et al. 2001
intron 14 c.1681+5G>A p.Q533_N561del splice, exon 14 skipping Stadler et al. 2006
intron 14 c.1682-3A>G p.N561Kfs*10 splice/frameshift Dantas et al. 2005
exon 15 c.1695_1700del p.V566_T567del deletion Morscher et al. 2012
exon 16 c.1750C>T p.Q584* nonsense Uematsu et al. 2007
exon 16 c.1820delG p.S607Ifs*5 deletion/frameshift #103/ This study
exon 17 c.1882G>T p.E628* nonsense #50/ This study
exon 17 c.1930G>T p.E644* nonsense #43a, 43b/ Dantas et al. 2005
exon 18 c.2009_2043del35 p.A670Dfs*34 deletion/frameshift #138/ This study
exon 19 c.2079delA p.V694* nonsense #60, 70a/ Holzinger et al. 2001
exon 19 c.2088dupA p.V697Sfs*19 insertion/frameshift #46/ Dantas et al. 2005
exon 19 c.2123dupA p.H708Qfs*8 insertion/frameshift #74/ This study
a Found in our laboratory in a heterozygous individual, not yet published.
b Published in the original paper as c.250_251delAG (p.R84Kfs*9), however AG is not found at this position in the reference sequence, but GA instead.
c Published in the original paper as p.G214IfsX5, nomenclature has been adapted to new approved guidelines.
d Published in the original paper as c.1264insG, Q421fs(+1), nomenclature has been adapted to new approved guidelines.
e Mainly found in patients from the Faroe Islands.
(NG_008100.1 [GenBank at the NCBI] was used as reference sequence. Consensus nomenclature according to approved guidelines (http://www.hgvs.org/
mutnomen/))
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Table 6 Overview on 68 MCCC2 mutant alleles and their consequences
Exon/Intron Nucleotide change
at cDNA level
Amino acid change
(at RNA level)
Consequence Patients, in whom this mutation
was found in this study/ Reference
of first description of the mutation
exon 1 c.116C>T p.S39F missense #80/ Dirik et al. 2008
exon 1 c.127C>T p.Q43* nonsense #32/ Dantas et al. 2005
exon 3 c.214C>T p.R72* nonsense #40/ Dantas et al. 2005
exon 3 c.243dupT p.L81Ifs*7a insertion/frameshift Stadler et al. 2006
intron 3 c.281+5G>A p.? splice Stadler et al. 2006
intron 3 c.281+5G>T p.G67Lfs*35b splice/exon 3 skippingb Gallardo et al. 2001
intron3 c.282-1G>C p.S95_G128delc splice/exon 4 skipping #33/ Dantas et al. 2005
exon 4 c.295G>C p.E99Q missense #24, 29, 90, 91/ Baumgartner
et al. 2001, Holzinger et al. 2001
exon 4 c.302C>T p.S101F missense Stadler et al. 2006
exon 4 c.351_353delTGG p.G118del deletion #51, 55/ This study
intron 4 c.383+1G>T p.? splice Stadler et al. 2006
intron 4 c.384-2A>G p.? splice Stadler et al. 2006
exon 5 c.392G>T p.C131F missense #99a/ This study
exon 5 c.416_427del12ins16 p.T139_G143>RWVPGEfs*35 deletion/insertion/frameshift #40, 66/ Dantas et al. 2005
exon 5 c.436T>A p.Y146N missense #66/ This study
exon 5 c.455A>C p.K152T missense #72/ This study
exon 5 c.463C>T p.R155W missense #44, 77/ Dantas et al. 2005
exon 5 c.464G>A p.R155Q missense #22, 63, 67/ Baumgartner et al. 2001
exon 5 c.469C>T p.Q157* nonsense #23/ Dantas et al. 2005
exon 5 c.499T>C p.C167R missense Gallardo et al. 2001
exon 5 c.505T>G p.Y169D missense #100/ This study
intron 5 c.512-1G>Ad p.? splice #82a, 82b/ Baumgartner et al. 2001
exon 6 c.517dupT p.S173Ffs*25 insertion/frameshift #39, 85/ Baumgartner
et al. 2001,Gallardo et al 2001
exon 6 c.518C>T p.S173L missense #108, 137/ Baumgartner et al. 2001
exon 6 c.538C>T p.R180* nonsense #58/ Stadler et al. 2006
exon 6 c.568C>T p.H190Y missense Dantas et al. 2005
exon 6 c.569A>G p.H190R missense Uematsu et al. 2007
exon 6 c.577C>T p.R193C missense Baumgartner et al. 2001
exon 6 c.578G>A p.R193H missense Stadler et al. 2006
exon 6 c.592C>T p.Q198* nonsense Uematsu et al. 2007
exon 6 c.599T>A p.I200N missense #85/ This study
exon 7 c.652G>A p.A218T missense Gallardo et al. 2001
exon 7 c.653C>T p.A218V missense Morscher et al. 2012
exon 7 c.653_654delCAinsTT p.A218V missense Uematsu et al. 2007
exon 7 c.659G>A p.G220E missense #55/ This study
exon 7 c.671C>T p.P224L missense #78/ This study
exon 7 c.710G>A p.G237D missense #92/ This study
exon 8 c.797A>Te p.H266Le missense Stadler et al. 2006
exon 8 c.803G>C (r.785_803del) p.R268T (p.G262_R268delfs*5) missense/splice #21, 52, 64/ Holzinger
et al. 2001, Dantas et al. 2005
exon 9 c.838G>T p.D280Y missense Uematsu et al. 2007
exon 9 c.845A>G p.H282R missense #34/ Dantas et al. 2005
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that samples for confirmatory diagnosis are more likely to
be obtained from symptomatic subjects than from asymp-
tomatic individuals. Additionally, the clinical phenotype of
MCC deficiency is still not well-defined.
In our study population the most common clinical fea-
tures were acute episodes of metabolic acidosis with vomit-
ing, hypoglycemia and acidosis, muscular symptoms such
as muscular hypotonia, muscle weakness and muscle pain
Table 6 Overview on 68 MCCC2 mutant alleles and their consequences (Continued)
intron 9 c.903+6_903+9delTACG p.? splice/RNA nd #72/ This study
exon 10 c.929C>G p.P310R missense #42/ Baumgartner et al. 2001
exon 10 c.994C>T p.R332* nonsense Dantas et al. 2005
exon 11 c.1015G>A p.V339M missense #67, 81, 90, 111/ Baumgartner
et al. 2001
exon 11 c.1019A>T p.D340V missense Stadler et al. 2006
exon 11 c.1054G>A(r.1054G>A +
r.1000_1072delins
r.999+858_r.999+922)
p.G352R +
(p.V334_G358delins
KFFMKYFLRLDLNSYNSTWQH)
missense/splice (skip exon
11, insert 64 bp from
intron 10)
Dantas et al. 2005
exon 11 c.1054_1055delGG p.G352Rfs*27f deletion/frameshift Uematsu et al. 2007
exon 11 c.1065A>T p.L355F missense Nguyen et al. 2011
intron 11 c.1073-12C>G
(r.1073_1216del+
r.1073insr.1073-48_r.1073-1)
2 transkripts:
(p.G358Vfs*6+p.
G358Afs*12)
splice/2 transkripts: exon
12 and 13 skipping,
insertion of 48 bp
from intron 11
#100/ This study
exon 12 c.1123G>T p.V375F missense #39/ Dantas et al. 2005
intron 12 c.1149+1G>T p.? splice #136 / This study
intron12 c.1149+5G>C p.? splice #92/ This study
exon 13 c.1208A>C p.N403T missense Stadler et al. 2006
exon 14 c.1300G>C p.V434L missense #126/ This study
exon 14 c.1309A>G(r.1309A>G+
r.1310_1373del64)
2 transkripts:
(p.I437V+p.I437Tfs*15)
missense/splice (cryptic
splice donor resulting in
deletion of the last 64 bp
of exon 14)
#111/ Baumgartner et al. 2001
exon 14 c.1367C>T p.A456V missense #37/ Dantas et al. 2005
exon 15 c.1423G>A p.G475R missense #125/ This study
exon 15 c.1423G>C p.G475R missense #127/ This study
exon 15 c.1430A>G p.Q477R missense Nguyen et al. 2011
exon 15 c.1465C>T p.Q489* nonsense Stadler et al. 2006
exon 16 c.1549G>A p.G517R missense Nguyen et al. 2011
exon 16 c.1559A>C p.Y520S missense Nguyen et al. 2011
exon 16 c.1567A>G p.S523G missense #56, 69/ Morscher et al. 2011
intron 16 c.1574+1G>A p.F497Gfs*4g splice, exon 16 skipping #29, 30/ Dantas et al. 2005
exon 17 c.1624_1625dupGGh p.L543Vfs*11 insertion/frameshift Uematsu et al. 2007
exon 17 c.1663A>G p.K555E missense Stadler et al. 2006
exon 17 c.1690T>C p.X564QLE add 3 aa at C-terminus #26/ Dantas et al. 2005
(NG_008882.1 [GenBank at the NCBI] was used as reference sequence. Consensus nomenclature according to approved guidelines (http://www.hgvs.org/
mutnomen/)).
nd not detectable
a This mutation has been published as p.L81Lfs*7 in the original paper, nomenclature has been adapted to new approved guidelines.
b For this mutation “MCCB exon 3 skipping, frameshift after residue 66” has been published in the original paper, nomenclature has been adapted to new
approved guidelines.
c This mutation has been published as p.G94_S127del in the original paper, nomenclature has been adapted to new approved guidelines.
d This mutation has been published as In5ac-1G→A in the original paper, nomenclature has been adapted to new approved guidelines.
e This mutation has been published as c.979A>T, p.H266L in exon 8 in the original paper. However, c.979A>T would predict an Arginine to Tryptophan change in
position 327 (p.R327W). The Histidine to Leucine change in position 266 (p.H266L) could be caused by c.797A>T, therefore, a typing error cannot be excluded.
f This mutation has been published as p.G352RfsX26 in the original paper, nomenclature has been adapted to new approved guidelines.
g This mutation has been published as p.F497_V526>GfsX4 in the original paper, nomenclature has been adapted to new approved guidelines.
h This mutation has been published as c.1625_1626insGG in the original paper, nomenclature has been adapted to new approved guidelines.
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and neurological abnormalities including developmental
delay and seizures as well as attention deficit hyperactivity
disorders (Tables 1, 2, 3 and 4). The acute metabolic crises
reported in 12 patients are likely to be caused by the under-
lying metabolic defect. However, the causative attribution
of all other clinical signs, especially of unspecific chronic
neurologic symptoms such as mental retardation, attention
deficit disorders and fatigue to MCC deficiency remains
questionable. It could be speculated that these symptoms
might as well be caused by undiagnosed genetic defects
other than MCC deficiency. Such an additional genetic
disorder –though unprobable- would be more likely in
individuals that are the product of a consanguineous
union; thus a higher share of symptomatic individuals
would be expected in this subgroup when compared to
subjects whose parents are reported not to be consanguin-
eous. However, no significant difference in the clinical
manifestation rate between the two subgroups could be
shown (41% symptomatic patients in both subgroups, 12
of 29 individuals with reported parental consanguinity
versus 18 of 44 subjects with parents reported not to be
consanguineous).
Of the three lethal cases in our study cohort, two could
be attributed to a severe metabolic decompensation due
to MCC deficiency. The sudden cardiac death of a 9 year
old girl was shown to be caused by catecholaminergic
polymorphic ventricular tachycardia with mutations in the
RyR2 gene. Thus, in the cohort of 80 individuals of whom
clinical information was available, lethality that may be
associated with MCC deficiency was 2.5% (2/80).
Altogether, though the share of individuals with clinical
symptoms was higher in our study population, our data
underline the observation of Stadler and co-workers [6]
that compared to other organic acidemias, individuals with
MCC deficiency appear to have a significantly higher
tolerance toward metabolic stress; even complete absence
of MCC activity seems to cause clinical manifestations only
in association with environmental triggering factors in a ra-
ther small subgroup of individuals. Dietetic treatment is
usually not required. However, considering the frequency
of carnitine deficiency in our study population, regular
monitoring of free carnitine concentrations and – if neces-
sary - oral carnitine substitution seems to be warranted.
Also, an emergency regimen during intercurrent illness
may be advisable.
Biochemical phenotype/MCC activity
As shown in Tables 1, 2, 3 and 4 the vast majority of indivi-
duals displayed a typical biochemical phenotype with accu-
mulation of metabolites characteristic for MCC deficiency in
both blood and urine at the time of diagnosis. Mild eleva-
tions of one or more metabolites were the exception and
were not more common in asymptomatic individuals. A
completely unremarkable urine organic acid pattern was
detected in only one woman. However, the concentration of
C5OH in her blood was clearly elevated at the same time.
The phenomenon that mutations may cause a clear bio-
chemical phenotype in otherwise asymptomatic individuals
is well known from other inborn errors of metabolism
implemented in expanded NBS such as isovaleric acidemia
[42] or medium-chain acyl-CoA dehydrogenase deficiency
[43]. From the data available in this study we were able to
confirm earlier observations that in MCC deficiency there
is no apparent association between the biochemical and the
clinical phenotype and that a mild biochemical phenotype
does not seem to be a predictor of a mild clinical expres-
sion [2,6,11]. Furthermore, we have recently shown that
also individuals who are carriers of a single mutation at the
MCCC1 locus and have residual MCC activity greater than
20% of control may present with a mild biochemical pheno-
type characteristic for MCC deficiency [12].
In all but two individuals MCC activity in fibroblasts was
severely reduced combined with normal activity of PCC. As
for the biochemical phenotype, we were not able to
Table 7 Expression of MCCC1 and MCCC2 wildtype and
mutant alleles
Allele PCC and MCC activities (pmol/min/mg protein)*
Experiment 1 Experiment 2
PCC MCC %** PCC MCC %**
MCCC1-wildtype 311 193 100 331 157 100
vector only 335 0 0 377 0.3 0.2
MCCC1-p.E288G 283 0 0 352 1.8 1.1
MCCC1-p.G379D 293 0 0 326 0 0
MCCC1-p.I434M 330 87.6 45.4 324 74.5 47.4
MCCC2-wildtype 377 75.4 100 341 49.4 100
vector only 364 0.3 0.4 346 0 0
MCCC2-p.S39F 398 29.6 39.3 368 24.8 50.2
MCCC2-p.G118del 366 10.8 14.3 342 3.2 6.5
MCCC2-p.Y146N 341 58.7 77.9 372 44.1 89.3
MCCC2-p.H282R 301 9.6 12.7 339 2.3 4.7
MCCC2-p.A456V 265 2.0 2.7 340 0.1 0.2
MCCC2-p.S523G 313 56.1 74.4 344 30.9 62.6
MCCC2-wildtype 335 76.9 100 446 43.5 100
vector only 371 0 0 540 0.5 1.1
MCCC2-p.V434L 295 56.6 73.7 449 33.5 77.0
MCCC2-p.G475R 290 33.7 43.8 414 21.1 48.5
Transient expression was performed in transformed MCCC1 and MCCC2 deficient
fibroblasts followed by the assay of propionyl-CoA carboxylase (PCC) and 3-
methylcrotonyl-CoA carboxylase (MCC) activities. Transfection with an empty vector
(vector only) was used as negative control.
*activities are the mean of duplicate determination.
** % of MCC activity of simultaneously expressed wildtype allele.
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demonstrate a correlation between the residual enzyme ac-
tivity and the clinical phenotype. When individuals with a
less severe deficiency of MCC as indicated by a PCC/MCC
ratio of< 50 were compared to a subgroup with a more se-
vere deficiency and a ratio of> 50, the manifestation of
clinical symptoms was not significantly more common in
the latter group (40% (6/15) versus 47% (22/47),
respectively).
Molecular heterogeneity
Molecular genetic analysis of 83 subjects enrolled in the
current study revealed a total of 31 new MCCC1 (n = 15)
and MCCC2 (n = 16) mutations considered to be causa-
tive of MCC deficiency. This brings up the total of
mutations published to date to 64 for MCCC1 and 68
for MCCC2 (Tables 5 and 6) [2-12].
In our study cohort MCCC2 mutations were 1.7 times
more common than MCCC1 mutations (63% versus 37%,
respectively).
Tables 5 and 6 illustrate a broad genetic heterogeneity at
both the MCCC1 and MCCC2 locus. Mutations are dis-
tributed along almost the entire coding regions of both
genes with the exception of exon 2 of both the MCCC1
and MCCC2 gene which do not host any mutations.
Figure 2 Western blot analysis of expressed MCCC1 wildtype and mutant proteins. Constructs with MCCC1 wildtype and 3 mutant cDNAs
in pTracer vector were transfected into MCCC1 deficient reference cell lines by electroporation and harvested 48 hours later for Western blot
analysis. 50 μg of protein were used per lane. The MCCC1 subunit was visualized by a) immunostaining using β-actin (4 μg) as control, or by b)
colorimetric reaction after coupling with avidin-alkaline phosphatase. Transfection with an empty vector (vector only) was used as a negative
control. For further details see “Methods”.
Figure 3 Western blot analysis of expressed MCCC2 wildtype and mutant proteins. Constructs with MCCC2 wildtype and 8 mutant cDNAs
in pTracer vector were transfected into MCCC2 deficient reference cell lines by electroporation and harvested 48 hours later for Western blot
analysis. 50 μg of protein were used per lane. The MCCC2 subunit was visualized by immunostaining using β-actin (6 μg) as control. Transfection
with an empty vector (vector only) was used as a negative control. For further details see “Methods”.
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The majority of mutations are private. Notably, in our co-
hort of 78 families only 5 MCCC1 and 10 MCCC2 muta-
tions have been found in more than one family. The most
common mutation was the p.R385S mutation in MCCC1
which was found in 8 individuals and 9 alleles. This mis-
sense mutation has been shown to have a dominant nega-
tive effect in the presence of the wild type allele and may
lead to biochemical and clinical abnormalities in heterozy-
gous individuals [44]. However, in agreement with earlier
reports p.R385S appears not to be a predictor of a particular
phenotype and has been found in severely affected patients
as well as in asymptomatic individuals (this study, [2,3,44].
Another recurring mutation was c.1526delG (p.C509Sfs*14)
which was the only mutation found in all 3 individuals
from the Faroe Islands suggesting that this is a founder
mutation.
Novel mutations
Among the novel mutations identified in this study
(shown in bold in Tables 5 and 6) the most common
were missense mutations (n = 18). Frameshift (n = 5) and
splice site mutations (n = 5) were more frequent than
nonsense mutations (n = 2) and small deletions (of a sin-
gle amino acid) (n = 1).
We assume deleterious functional consequences for the
frameshift mutations [MCCC1 c.658_662delTCAGA (p.
S220Tfs*15), c.1193_1194delTG (p.V398Gfs*19), c.1820delG
(p.S607Ifs*5), c.2009_2043del35 (p.A670Dfs*34), c.2123dupA
(p.H708Qfs*8)], the splice site mutations [MCCC1
c.639+ 2 T>A (p.S164Rfs*3); MCCC2 c.903 + 6_903+
9delTACG (p.?), c.1073-12 C>G (p.G358Vfs*6 + p.
G358Afs*12), c.1149+ 1 G>T (p.?), c.1149+ 5 G>C
(p.?)] and the nonsense mutations [MCCC1 c.1114 C>T
(p.Q372*), c.1882 G>T (p.E628*)] because they result in
truncated proteins lacking functionally important domains
such as the BC (in MCCC1) or CT (in MCCC2) domains
[2,45].
The MCCC2 splice site mutation c.1073-12 C>G is
interesting since sequence analysis of cDNA of patient
#107 revealed two overlapping sequences. One transcript
showed exon 12 and 13 skipping, while the other transcript
contained an inframe insertion of a 48 bp sequence from
intron 11. No wildtype transcript could be detected. It is
conceivable that the c.1073-12 C>G mutation creates a
cryptic splice site resulting in partial skipping of exons 12
and 13 and in the partial insertion of an additional exon.
Among the novel MCCC1 missense mutations all var-
iants [p.M65L, p.G180V, p.A268D, p.E288G, p.G379D,
p.I434M, p.V439M] change residues within the BC
domain, while all novel MCCC2 missense mutations
[p.C131F, p.Y146N, p.K152T, p.Y169D, p.I200N, p.G220E,
p.P224L, p.G237D, p.V434L, p.G475R, p.G475R] affect the
CT domain of the MCCC2 protein. During the final stage
of this manuscript preparation, the crystal structure of P.
aeruginosa MCC holoenzyme, with >50% sequence iden-
tity to the human counterpart (Additional file 1: Figure S1
Additional file 2: Figure S2), was reported [46]. The struc-
ture reveals a markedly different holoenzyme architecture
compared to other biotin-dependent enzymes, hence
providing an unprecedented opportunity to understand
MCCC1/2 missense mutations in the protein context. We
rationalize that the reported variants are very likely to
affect protein function for the following reasons: 1) No
other alterations in the MCCC1 and MCCC2 gene have
been found despite sequencing of the complete coding
regions of both genes in all individuals carrying one of
those mutations; 2) Amino acid sequence alignments
revealed that all but one [MCCC2 c.599 T>A (p.I200N)]
of the nucleotide changes affect highly conserved residues
across species (PolyPhen2, //genetics.bwh.harvard.edu/
pph/), and many are also conserved among other biotin-
dependent enzymes (Additional file 1: Figure S1, Add-
itional file 2: Figure S2); 3) A majority of the mutations are
mapped onto the catalytic core of the MCCC1 BC domain
and the substrate binding region of the MCCC2 CT do-
main (yellow spheres in Figure 4A), suggesting their func-
tional importance; 4) Most of the missense mutations
alter the physicochemical properties of the amino acid
position (e.g. replacing small with bulky, unipolar with
polar, or uncharged with charged residues) and hence are
likely to affect the local molecular environment; 5) None
of these 19 variants is present in the 1000 Genomes Pro-
ject dataset (//www.1000genomes.org/home); 6) It is of
note that some MCCC1/2 missense mutations, affecting
residues at the inter-subunit interface (Figure 4B and C),
may affect not only the corresponding domain fold but
also disrupt the assembly of the α and β subunits into the
functional hetero-dodecamer.
Expression data
So far, functional consequences of only 4 MCCC1 and 8
MCCC2 mutant alleles have been proven by expression in
a mammalian expression system [2,11]. In this study we
expressed 3 further MCCC1 and 8 MCCC2 mutations
(Table 7) including those expected to show residual en-
zyme activity based on studies in fibroblasts. Expression of
two of the 3 MCCC1 [p.E288G and p.G379D] and one of
the 8 MCCC2 [p.G118del] mutants resulted in severely
reduced MCC activity and protein levels on Western blot
analysis confirming deleterious consequences of these
mutations on enzyme function and protein stability.
Glu288 and Gly379 in MCCC1 are highly conserved resi-
dues in the BC domains among biotin-dependent enzymes
(Additional file 1: Figure S1). In the P. aeruginosa MCC
holoenzyme structure, Glu288 forms an ionic pair inter-
action (Glu288-Arg444) to hold two secondary structure
elements together, as observed in the homologous struc-
tures of ACC1 (Glu427-Arg604; PDB code 2YL2), ACC2
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(Glu533-Arg710; 3GLK) and PCCα (Glu302-Arg459;
3N6R). Gly379 is expected to be at an invariant position at
the beginning of a nearby β-strand, directly facing the
aforementioned arginine residue. Mutations at Glu288
and Gly379 therefore may disrupt the packing of these
secondary structure elements (Figure 4D).
Deleterious effects of two further MCCC2 mutant alleles
[p.H282R and p.A456V] were shown by severely reduced
MCC activities of less than 13% of simultaneously
expressed wildtype activity. However, in both cases protein
levels were normal, and the two affected residues His282
and Ala456 are located at the monomeric surface,
indicating that these mutations do not affect the stability
of the protein. Expression of all other mutant alleles
[MCCC1 p.I434M, MCCC2 p.S39F, p.Y146N, p.V434L, p.
G475R and p.S523G] yielded considerable levels of residual
MCC activity (Table 7). The equivalent of MCCC1 Ile434
in other biotin-dependent carboxylases can be Phe or
Leu (Additional file 2: Figure S2), suggesting that substi-
tution to a Met (similar size to Phe and Leu) in the p.
I434M mutation may well be tolerated. All mutated resi-
dues from the 7 MCCC2 missense constructs (p.S39F, p.
Y146N, p.282R, p.V434L, p.A456V, p.G475R, p.S523G) are
at least partially exposed to the surface of the monomer,
and not buried within the enzymatic core. Fibroblasts of 4
individuals (No 69, 80, 126 and 127) each homozygous for
one of these mutations also showed residual enzyme activ-
ity, which was, however, much lower (6.2 – 31% of the
median control value) than the activities of the expressed
mutant alleles (39% - 77% of simultaneously expressed
wildtype activity). Inspite of the high MCC activities after
expression Western blot analysis revealed severely reduced
protein levels in 2 cases (MCCC2 p.S39F, p.V434L). Normal
levels of protein were expressed by two other mutant alleles
(MCCC2 p.S523G, p.G475R). Even more drastic differences
were found between MCC activity of the expressed protein
(45%-89%) and that of fibroblasts (3.2% - 7.6%) that are
compound heterozygous for the MCCC1 mutation p.
I434M andMCCC2mutations p.Y146N and p.S523G (indi-
viduals No 56, 66 and 74). Thus, expression studies may
not demonstrate/identify the specific functional abnormal-
ities for at least some of the mutant alleles with residual en-
zyme activity. However, no other mutations were found
despite sequencing of the complete coding region of both
MCC genes.
Genotype-phenotype correlations
Our data confirm previous studies reporting no clear
genotype-phenotype correlation in MCC deficiency [3,6,11]
suggesting that factors other than the genotype at the MCC
loci have a major influence on the clinical phenotype [11].
In line with this we identified clinically asymptomatic fe-
male adults carrying null mutations in homozygosity and
siblings of which one was asymptomatic and the other
showed neurologic symptoms compatible with influence of
Figure 4 Mapping of missense mutations onto the P. aeruginosa MCC holoenzyme structure. (A) Mapping of the novel missense mutations
(yellow spheres) onto the P. aeruginosa MCC holoenzyme structure (PDB code 3U9T), showing that they are clustered in the BC domain of MCCC1
(pink) or the CT domain of MCCC2 (green). (B) and (C) Mutation sites of Asn200, Gly220, Pro224 and Gly475 are located at the interface between two
MCCC2 subunits (coloured green and purple). (D) Structural environment of the MCCC1 Glu288 and Gly379 mutation sites. All the residues shown in
sticks are conserved between the human and P. aeruginosa enzymes. The Glu288-Arg444 ionic interaction is indicated by dashed lines.
Grünert et al. Orphanet Journal of Rare Diseases 2012, 7:31 Page 22 of 24
http://www.ojrd.com/content/7/1/31
environmental factors on the clinical outcome of affected
individuals.
None of the mutations found in asymptomatic indivi-
duals with MCC deficiency detected by NBS was preva-
lent in this group, which is in contrast to other inborn
errors of metabolism such as isovaleric acidemia [42] or
medium-chain acyl-CoA dehydrogenase deficiency [43].
Consequently, genotyping still appears to be of no help
in predicting the clinical outcome of individuals with
MCC deficiency.
Conclusions
Our data confirm that MCC deficiency despite its low
penetrance can lead to a severe clinical phenotype resem-
bling classical organic acidurias. However, neither the geno-
type nor the biochemical phenotype is helpful in predicting
which affected individual is at risk of developing clinical
symptoms.
Additional files
Additional file 1: Figure S1. Amino acid sequence alignment of
human MCCC1. Amino acid sequence alignment of human MCCC1
(hMCCC1, Uniprot Q96RQ3), as well as the structurally characterized P.
aeruginosa MCCC1 (paMCCC1, Q9I299), Ruegeria pomeroyi PCCα (bPCCA,
Q5LUF3), human ACC1 (hACC1, Q13085) and ACC2 (hACC2, O00763).
Novel MCCC1 missense mutations are asterisked. The electrostatic
interaction between Glu288 and Arg444 in MCCC1 is highlighted in
green.
Additional file 2: Figure S2. Amino acid sequence alignment of
human MCCC2.Amino acid sequence alignment of human MCCC2
(hMCCC2, Uniprot Q9HCC0), as well as the structurally characterized P.
aeruginosa MCCC2 (paMCCC2, Q9I297), Propionibacterium shermanii
methylmalonyl-CoA carboxyltransferase (psMMCC, Q8GBW6), Streptomyces
coelicolor PCCβ (scPCCB, Q9X4K7) and Roseobacter denitrificans PCCα
(bPCCA, Q168G2). Novel MCCC2 missense mutations are asterisked.
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